Full name

A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants

NCT Number
NCT05412030
Geography
US
Locations

United States

Primary Endpoints
  • Percentage of participants with solicited injection site events. Day 1 through Day 7 post vaccination
  • Percentage of participants with solicited systemic events. Day 1 through Day 7 post vaccination
  • Percentage of participants with AEs. Day 1 through Day 30
  • Percentage of participants with serious adverse events (SAEs). Day 1 through study completion, an average of 6 months post last vaccine adminstration
External Link
https://clinicaltrials.gov/study/NCT05412030
Order
1
Disease
Pn-MAPS
Menu title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Version
ATS 2025
Phase
2
Status
Active, not recruiting